Solventum Co. (NYSE:SOLV) Shares Sold by Asset Dedication LLC

Asset Dedication LLC cut its position in shares of Solventum Co. (NYSE:SOLV) by 22.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,433 shares of the company’s stock after selling 423 shares during the quarter. Asset Dedication LLC’s holdings in Solventum were worth $95,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of SOLV. Blue Trust Inc. grew its holdings in Solventum by 2.1% during the fourth quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock worth $549,000 after acquiring an additional 161 shares during the period. MML Investors Services LLC raised its holdings in shares of Solventum by 3.2% in the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock worth $373,000 after purchasing an additional 168 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its stake in Solventum by 4.2% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock valued at $346,000 after purchasing an additional 200 shares during the last quarter. IVC Wealth Advisors LLC boosted its holdings in Solventum by 5.0% during the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after buying an additional 318 shares in the last quarter. Finally, KKM Financial LLC grew its position in Solventum by 7.9% in the third quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock worth $304,000 after buying an additional 319 shares during the last quarter.

Solventum Stock Performance

Shares of SOLV opened at $75.21 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The business’s 50-day moving average is $70.00 and its 200-day moving average is $66.98. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.23). The business had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.05 billion. On average, analysts anticipate that Solventum Co. will post 6.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on SOLV. Morgan Stanley increased their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Mizuho began coverage on Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price for the company. Piper Sandler lifted their price target on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Finally, Stifel Nicolaus assumed coverage on shares of Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Solventum has an average rating of “Hold” and an average price target of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.